ColdVentures Unveils First-of-its-Kind, Class 1 FDA Medical Device ColdVest to Prevent Heat-Related Deaths

Portable Vest Protects Military Personnel, Outdoor Workers, Athletes, Students and More Without Requiring Electricity or Refrigeration Created for Rapid Emergency Cooling Before EMS Arrival

With annual heat-related deaths projected to increase 370 percent by 2050, rising temperatures and extreme heat events pose a significant threat to humans. As heat waves intensify, ColdVentures, a medical device company developing innovative new technologies to combat heat-related deaths, has unveiled ColdVest, a first-of-its-kind, Class 1 FDA portable emergency cooling device to protect people from heat-related brain or organ damage and death before emergency medical services arrive.

“Heat-related deaths have been increasing dramatically in recent years, with estimates ranging from tens of thousands to hundreds of thousands of incidents annually worldwide. 2023 alone set a heat death record in the United States. We need to look beyond      treatment methods like ice baths and adopt new technologies to save lives, as heat stroke is preventable in most cases,” said Tracie Wagman, ColdVentures Co-Founder and CEO. “ColdVest is the only portable emergency device available for heat stroke that does not require electricity or refrigeration. Given that people endured, on average, 86 days of health-threatening high temperatures last year globally, ColdVest has the potential to save thousands of lives around the globe each year.”

Heat stroke poses a particularly deadly threat to military personnel performing strenuous activities and wearing heavy gear in scorching environments; outdoor workers including construction crews, farmers and landscapers who are exposed to direct sunlight and high temperatures for long hours; firefighters battling blazes; and athletes training and competing in hot weather conditions. Heat stroke is especially dangerous for young athletes or those unaccustomed to extreme temperatures.

People suffering from heat stroke typically have 30 minutes before suffering permanent harm. In just under three minutes, ColdVest can reduce core body temperatures up to five degrees and stabilize an individual. Using patented endothermic cooling technology, ColdVest does not require electricity, refrigeration, ice or special storage. To use, add three liters of liquid to ColdVest’s integrated bladder, which then spreads throughout the vest to rapidly activate internal cooling chemicals. ColdVest is then placed over the torso of an individual for immediate relief. To learn more, visit coldvest.com.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”